Amylovis-201 is a new dual-target ligand, acting as an anti-amyloidogenic compound and a potent agonist of the σ1 chaperone protein

MLA

Laura García-Pupo, et al. “Amylovis-201 Is a New Dual-Target Ligand, Acting as an Anti-Amyloidogenic Compound and a Potent Agonist of the Σ1 Chaperone Protein.” Acta Pharmaceutica Sinica B, vol. 14, no. 10, Oct. 2024, pp. 4345–59. EBSCOhost, https://doi.org/10.1016/j.apsb.2024.06.013.

APA

Laura García-Pupo, Lucie Crouzier, Alberto Bencomo-Martínez, Johann Meunier, Axelle Morilleau, Benjamin Delprat, Marquiza Sablón Carrazana, Roberto Menéndez Soto del Valle, Tangui Maurice, & Chryslaine Rodríguez-Tanty. (2024). Amylovis-201 is a new dual-target ligand, acting as an anti-amyloidogenic compound and a potent agonist of the σ1 chaperone protein. Acta Pharmaceutica Sinica B, 14(10), 4345–4359. https://doi.org/10.1016/j.apsb.2024.06.013

Chicago

Laura García-Pupo, Lucie Crouzier, Alberto Bencomo-Martínez, Johann Meunier, Axelle Morilleau, Benjamin Delprat, Marquiza Sablón Carrazana, Roberto Menéndez Soto del Valle, Tangui Maurice, and Chryslaine Rodríguez-Tanty. 2024. “Amylovis-201 Is a New Dual-Target Ligand, Acting as an Anti-Amyloidogenic Compound and a Potent Agonist of the Σ1 Chaperone Protein.” Acta Pharmaceutica Sinica B 14 (10): 4345–59. doi:10.1016/j.apsb.2024.06.013.